scholarly journals Livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) colonisation and infection among livestock workers and veterinarians: a systematic review and meta-analysis

2020 ◽  
pp. oemed-2020-106418
Author(s):  
Chen Chen ◽  
Felicia Wu

ObjectivesMethicillin-resistant Staphylococcus aureus (MRSA) is an increasing public health concern worldwide. The objective of this study was to calculate a summary odds ratio (OR) of livestock-associated MRSA colonisation and infection in humans, and to determine specific risk factors in livestock production contributing to MRSA colonisation.MethodsWe screened PubMed and Embase for studies published from 2005 to 2019 inclusive, reporting livestock-associated (LA)-MRSA colonisation and infection among livestock workers/veterinarians, their families, and community members not regularly exposed to livestock. The primary outcome of interest was the OR of LA-MRSA colonisation comparing exposed and control groups. Quality was assessed according to the Newcastle-Ottawa quality assessment scale. A meta-analysis using a random-effects model was conducted to calculate a pooled OR. The heterogeneity in the meta-analysis was assessed using the I² method, and publication bias was evaluated using funnel plots.ResultsA total of 3490 studies were identified by the search, with 37 studies including 53 matched exposed-control groups and 14 038 participants eligible for the meta-analysis. The pooled OR for LA-MRSA among livestock workers and veterinarians is 9.80 (95% CI 6.89 to 13.95; p=0.000; I2=73.4), with no significant publication bias (Egger’s p=0.66). The OR for swine workers was highest at 15.41 (95% CI 9.24 to 25.69), followed by cattle workers (11.62, 95% CI 4.60 to 29.36), veterinarians (7.63, 95% CI 3.10 to 18.74), horse workers (7.45, 95% CI 2.39 to 23.25), livestock workers (5.86, 95% CI 1.14 to 30.16), poultry workers (5.70, 95% CI 1.70 19.11), and industrial slaughterhouse workers (4.69, 95% CI 1.10 to 20.0).ConclusionsLivestock workers, particularly swine farmers, are at significantly higher risk for LA-MRSA colonisation and subsequent infection. These results support the need for preventive practices to reduce LA-MRSA risk among those who handle and treat livestock.Trial registration numberCRD42019120403.

2019 ◽  
Author(s):  
Siobhan Hugh-Jones ◽  
Sophie Beckett ◽  
Pavan Mallikarjun

Schools are promising sites for the delivery of prevention and early intervention programs to reduce child and adolescent anxiety. It is unclear whether universal or targeted approaches are most effective. This review and meta-analysis examines the effectiveness of school-based indicated interventions and was registered with PROSPERO [CRD42018087628].MEDLINE, EMBASE, PsycINFO and the Cochrane Library were searched for randomised controlled trials comparing indicated school programs for child and adolescent anxiety to active or inactive control groups. Twenty original studies, with 2076 participants, met the inclusion criteria and 18 were suitable for meta-analysis. Sub-group and sensitivity analyses explored intervention intensity, delivery agent and control type. A small beneficial effect was found for indicated programs compared to controls on self-reported anxiety symptoms at post-test (g = -0.28, CI = -0.50, -0.05, k= 18). The small effect was maintained at 6 (g = -0.35, CI= -0.58, -0.13, k = 9) and 12 months (g = -0.24, CI = -0.48, 0.00, k = 4). Based on two studies, >12 month effects were very small (g = -0.01, CI= -0.38, 0.36). No differences were found based on intervention intensity, delivery agent and control type. There was evidence of publication bias and a relatively high risk of contamination in studies. Findings support the value of school based indicated programs for child and adolescent anxiety. Effects at 12 months outperform many universal programs. High quality, randomised controlled and pragmatic trials are needed, with attention control groups and beyond 12 month diagnostic assessments are needed.


PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e52722 ◽  
Author(s):  
Vanja M. Dukic ◽  
Diane S. Lauderdale ◽  
Jocelyn Wilder ◽  
Robert S. Daum ◽  
Michael Z. David

2019 ◽  
Author(s):  
Eissa Soleymani ◽  
Fariba Faizi ◽  
Rashid Heidarimoghadam ◽  
Lotfollah Davoodi ◽  
Younes Mohammadi

Abstract Background findings on association of Toxoplasmosis and suicide is contradictory. This paper aimed to resolve this uncertainty with help of Meta-analysis. Methods using keywords include “Toxoplasmosis” and “suicide” and the relayed synonyms in international databases such as ISI, Medline and Scopus, we found the relevant studies. The eligible studies included into Meta-analysis phase. Random effect approach was used to combine the results. Results out of 150 initial studies, 16 were included into meta-analysis. Odds of suicide in person with toxoplasmosis was 47% (OR: 1.47, 95%CI; 1.20 to 1.79) higher than of that without toxoplasmosis. Test for publication bias was not statistically significant, which indicate absence of likely publication bias. Conclusion This study confirm which toxoplasmosis is a potential risk factor for suicide. To reduce cases of suicide attributable to Toxoplasmosis, it deserving the measures to prevent and control of transmission of toxoplasmosis should be taken.


2018 ◽  
Vol 7 (3) ◽  
pp. 225-229
Author(s):  
Nur Amira Mohd Shamsuddin ◽  
◽  
Dayang Fredalina Basri ◽  

Methicillin-resistant Staphylococcus aureus (MRSA) is a global health concern that has caused nosocomial and community infections over the past decade. The emergence of multi-drug resistant strains and limitations of present antimicrobial drugs have led to continuous search for natural products as curative agents for MRSA infections. Canarium odontophyllum Miq., locally known as dabai, has been considered an alternative phytotherapeutic treatment for MRSA. The aim of this study was to evaluate the bacteriostatic activity of an acetone extract from C. odontophyllum leaves against MRSA. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the extract against the ATCC 33591 and Mu50 strains were determined using the broth microdilution method, and a time-kill assay was employed to assess the type of bacteriostatic action of the extract against the Mu50 strain only. The MIC and MBC values of the extract against Mu50 were 312.5 µg/ml and 625 µg/ml, respectively, whereas the MIC and MBC values for ATCC 33591 were 625 µg/ml and 1,250 µg/ml, respectively, confirming the bacteriostatic effect against both MRSA strains. A time-kill assay showed that the acetone extract of C. odontophyllum leaves exhibited concentrationdependent bacteriostatic action against the Mu50 strain at 1/2× MIC, 1× MIC and 2× MIC. However, the extract was bactericidal only at the highest concentration (4× MIC) with a reduction in cell viability of more than 3 log10 within 24 hours. These findings confirm that an acetone extract from C. odontophyllum leaves inhibited growth of MRSA at low concentration and could be utilised as an alternative anti-MRSA agent in immune uncompromised hosts


2021 ◽  
Author(s):  
Chun Chen ◽  
ZeMei Zhou ◽  
Jing Zhang

Abstract Background: Since December 2019, COVID-19 has spread to the world which leads to a global health threat. We aimed to investigate the effectiveness of tocilizumab on COVID-19 patients.Methods: We systematically searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and WHO international Clinical Trials Registry Platform (ICTRP) from their inception to March 10, 2021 for randomized controlled trials (RCTs) on tocilizumab supplementation in adults with COVID-19 disease. The primary outcomes were mortality at 28-30 day and 60-day, incidence of mechanical ventilation (MV), composite outcome of death or MV, time to hospital discharge, and intensive care unit (ICU) admissions. A random-effects meta-analysis model was used to pool studies. Results: Eleven studies with a total of 6,579 patients were included in our meta-analysis, of which 3,406 and 3,173 were respectively assigned to the tocilizumab and control groups. Tocilizumab could significantly reduce 28-30 day mortality (RR = 0.89, 95% CI 0.80-0.99, P = 0.04), incidence of MV (RR= 0.79, 95% CI 0.71-0.89, P = 0.0001), composition outcome of MV or death (RR = 0.81, 95% CI 0.72-0.90, P = 0.0002), time to hospital discharge (HR = 1.30, 95% CI 1.16-1.45, P < 0.00001 ), ICU admissions (RR = 0.64, 95% CI 0.47-0.88, P = 0.006), serious infection (RR = 0.61, 95% CI 0.40-0.94, P = 0.02) and events of serious adverse advents (RR = 0.64, 95% CI 0.47-0.86, P = 0.004). There was no significant difference between tocilizumab and control groups in 60-day mortality and adverse events (AEs).Conclusions: Tocilizumab could reduce the short-term mortality, incidence of MV, composite outcome of death or MV, ICU admissions, serious infection and events of serious adverse advents, and shorten the time to hospital discharge in hospitalized patients with COVID-19. The optimal effective dose needs to be confirmed by further studies.


Sign in / Sign up

Export Citation Format

Share Document